Environmental Wireless Sensor Network Deployment in Food Industry: from Theory to Practice

The difficulty behind Wireless Sensor Network deployments in industrial environments not only resides in the number of nodes or the communication protocols but also in the real location of the sensor nodes and the parameters to be monitored. Sensor soiling, high humidity and unreachable locations, among others, make real deployments a very difficult task to plan. Even though it is possible to find myriad approaches for floor planners and deployment tools in the state of the art, most of these problems are very difficult to model and foresee before actually deploying the network in the final scenario. This work shows two real deployments in food factories and how their problems are found and overcome

The Granulocyte colony-stimulating factor produces long-term changes on gene and miRNA expression profiles in CD34+ cells from healthy donors

Granulocyte colony-stimulating factor is the most commonly used cytokine for the mobilization of hematopoietic progenitor cells from healthy donors for allogeneic stem cell transplantation. Although the administration of this cytokine is considered safe, knowledge about its long-term effects, especially in hematopoietic progenitor cells, is limited. On this background, the aim of our study was to analyze whether or not granulocyte colony-stimulating factor induces changes in gene and microRNA expression profiles in hematopoietic progenitor cells from healthy donors, and to determine whether or not these changes persist in the long-term. For this purpose, we analyzed the whole genome expression profile and the expression of 384 microRNA in CD34(+) cells isolated from peripheral blood of six healthy donors, before mobilization and at 5, 30 and 365 days after mobilization with granulocyte colony-stimulating factor. Six microRNA were differentially expressed at all time points analyzed after mobilization treatment as compared to the expression in samples obtained before exposure to the drug. In addition, 2424 genes were also differentially expressed for at least 1 year after mobilization. Of interest, 109 of these genes are targets of the differentially expressed microRNA also identified in this study. These data strongly suggest that granulocyte colony-stimulating factor modifies gene and microRNA expression profiles in hematopoietic progenitor cells from healthy donors. Remarkably, some changes are present from early time-points and persist for at least 1 year after exposure to the drug. This effect on hematopoietic progenitor cells has not been previously reported

Critical COPD respiratory illness is linked to increased transcriptomic activity of neutrophil proteases genes

BACKGROUND: Gene expression profiling (GEP) in cells obtained from peripheral blood has shown that this is a very useful approach for biomarker discovery and for studying molecular pathogenesis of prevalent diseases. While there is limited literature available on gene expression markers associated with Chronic Obstructive Pulmonary Disease (COPD), the transcriptomic picture associated with critical respiratory illness in this disease is not known at the present moment. FINDINGS: By using Agilent microarray chips, we have profiled gene expression signatures in the whole blood of 28 COPD patients hospitalized with different degrees of respiratory compromise.12 of them needed of admission to the ICU, whilst 16 were admitted to the Respiratory Medicine Service. GeneSpring GX 11.0 software was used for performing statistical comparisons of transcript levels between ICU and non-ICU patients. Ingenuity pathway analysis 8.5 (IPA) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) were used to select, annotate and visualize genes by function and pathway (gene ontology). T-test showed evidence of 1501 genes differentially expressed between ICU and non-ICU patients. IPA and KEGG analysis of the most representative biological functions revealed that ICU patients had increased levels of neutrophil gene transcripts, being [cathepsin G (CTSG)], [elastase, neutrophil expressed (ELANE)], [proteinase 3 (PRTN3)], [myeloperoxidase (MPO)], [cathepsin D (CTSD)], [defensin, alpha 3, neutrophil-specific (DEFA3)], azurocidin 1 (AZU1)], and [bactericidal/permeability-increasing protein (BPI)] the most representative ones. Proteins codified by these genes form part of the azurophilic granules of neutrophils and are involved in both antimicrobial defence and tissue damage. This “neutrophil signature” was paralleled by the necessity of advanced respiratory and vital support, and the presence of bacterial infection. CONCLUSION: Study of transcriptomic signatures in blood suggests an essential role of neutrophil proteases in COPD patients with critical respiratory illness. Measurement and modulation of the expression of these genes could present an option for clinical monitoring and treatment of severe COPD exacerbations

Cannabinoid derivatives exert a potent anti-myeloma activity both in vitro and in vivo

12 p.-6 fig.-1 tab.Although hematopoietic and immune system show high levels of the cannabinoid receptor CB2, the potential effect of cannabinoids on hematologic malignancies has been poorly determined. Here we have investigated their anti-tumor effect in multiple myeloma (MM). We demonstrate that cannabinoids induce a selective apoptosis in MM cell lines and in primary plasma cells of MM patients, while sparing normal cells from healthy donors, including hematopoietic stem cells. This effect was mediated by caspase activation, mainly caspase-2, and was partially prevented by a pan-caspase inhibitor. Their pro-apoptotic effect was correlated with an increased expression of Bax and Bak, a decrease of Bcl-xL and Mcl-1, a biphasic response of Akt/PKB and an increase in the levels of ceramide in MM cells. Inhibition of ceramide synthesis partially prevented apoptosis, indicating that these sphingolipids play a key role in the pro-apoptotic effect of cannabinoids in MM cells. Remarkably, blockage of the CB2 receptor also inhibited cannabinoid-induced apoptosis. Cannabinoid derivative WIN-55 enhanced the anti-myeloma activity of dexamethasone and melphalan overcoming resistance to melphalan in vitro. Finally, administration of cannabinoid WIN-55 to plasmacytoma-bearing mice significantly suppressed tumor growth in vivo. Together, our data suggest that cannabinoids may be considered as potential therapeutic agents in the treatment of MM.Grant sponsor: Junta de Andalucía; Grant numbers: PI-0355–2013 and AC-0062–2013; Grant sponsor: Instituto de Salud Carlos III;Grant numbers: PI14/02074 and CP12/03273.Peer reviewe

Demographic, clinical and antibody characteristics of patients with digital ulcers in systemic sclerosis: data from the DUO Registry

OBJECTIVES: The Digital Ulcers Outcome (DUO) Registry was designed to describe the clinical and antibody characteristics, disease course and outcomes of patients with digital ulcers associated with systemic sclerosis (SSc). METHODS: The DUO Registry is a European, prospective, multicentre, observational, registry of SSc patients with ongoing digital ulcer disease, irrespective of treatment regimen. Data collected included demographics, SSc duration, SSc subset, internal organ manifestations, autoantibodies, previous and ongoing interventions and complications related to digital ulcers. RESULTS: Up to 19 November 2010 a total of 2439 patients had enrolled into the registry. Most were classified as either limited cutaneous SSc (lcSSc; 52.2%) or diffuse cutaneous SSc (dcSSc; 36.9%). Digital ulcers developed earlier in patients with dcSSc compared with lcSSc. Almost all patients (95.7%) tested positive for antinuclear antibodies, 45.2% for anti-scleroderma-70 and 43.6% for anticentromere antibodies (ACA). The first digital ulcer in the anti-scleroderma-70-positive patient cohort occurred approximately 5 years earlier than the ACA-positive patient group. CONCLUSIONS: This study provides data from a large cohort of SSc patients with a history of digital ulcers. The early occurrence and high frequency of digital ulcer complications are especially seen in patients with dcSSc and/or anti-scleroderma-70 antibodies

Plasticidad del sistema glutamatérgico en la vía olfatoria de roedores sometidos a deprivación sensorial. Estudio del receptor mGluR1a en el bulbo olfatorio

[ES] Tesis doctoral sobre la plasticidad del sistema glutamatérgico en la vía olfativa de roedores sometidos a deprivación sensorial.[EN] Doctoral thesis on the plasticity of the glutamatergic system in the olfactory pathway of rodents subjected to sensory deprivation

Efecto antileucémico de derivados cannabinoides: un nuevo grupo terapéutico en LMA

2 p.-3 fig.Los cannabinoides, componentes activos del cannabis, se emplean como tratamiento paliativo en pacientes con cáncer en virtud de su efecto antiemético y analgésico. Además, hay evidencias de que estos compuestos inhiben el crecimiento de algunas células tumorales en animales de laboratorio. Estos compuestos actúan uniéndose a receptores específicos. Los principales receptores son el CB1 (mayoritario en SNC) y CB2 (en tejido hematopoyético). El objetivo de este estudio fue confirmar el efecto terapéutico de derivados cannabinoides sintéticos específicos del receptor CB2 en LMA.Peer reviewe

The Clinical Relevance of Molecular Genetics in Soft Tissue Sarcomas

Bone and soft tissue sarcomas are an infrequent and heterogeneous group of mesenchymal tumors including more than a hundred different entities attending to histologic patterns. Research into the molecular aspects of sarcomas has increased greatly in the last few years. This enormous amount of knowledge has allowed, for instance, to refine the classification of sarcomas, improve the diagnosis, and increase the number of therapeutical targets available, most of them under preclinical evaluation. However, other important key issues, such as sarcomagenesis and the cell of origin of sarcomas, remain unresolved. From a molecular point of view, these neoplasias are grouped into 2 main types: (a) sarcomas showing relatively simple karyotypes and translocations, which originate gene fusions (eg, EWS-FLI1 in Ewing sarcoma) or point mutations (eg, c-kit in the gastrointestinal tumors) and (b) sarcomas showing unspecific gene alterations, very complex karyotypes, and no translocations. The discovery of the early mechanisms involved in the genesis of sarcomas, the more relevant signaling pathways, and the development of genetically engineered mouse models could also provide a new individualized therapeutic strategy against these tumors. This review describes the clinical application of some of the molecular alterations found in sarcomas, some advances in the field of sarcomagenesis, and the development of animal models.Peer Reviewe

Derivados del indazol para el tratamiento del cáncer

[ES] Uso de una serie de compuestos indazólicos y sus derivados en la elaboración de un medicamento para su administración, sólo o en combinación con otro principio activo adecuado en el tratamiento de las gammapatías monoclonales, y más concretamente en el mieloma múltiple (MM).[EN] The invention relates to the use of a series of indazole compounds and the derivatives thereof in the production of a drug to be administered alone or combined with another suitable active ingredient in the treatment of cancer and, more specifically, the treatment of haematological cancer.Peer reviewedServicio Andaluz de Salud, Consejo Superior de Investigaciones Científicas (España)B1 Patente sin examen previ

Derivados del indazol para el tratamiento del cáncer

[ES] Uso de una serie de compuestos indazólicos y sus derivados en la elaboración de un medicamento para su administración, sólo o en combinación con otro principio activo adecuado en el tratamiento de las gammapatías monoclonales, y más concretamente en el mieloma múltiple (MM).[EN] The invention relates to the use of a series of indazole compounds and the derivatives thereof in the production of a drug to be administered alone or combined with another suitable active ingredient in the treatment of cancer and, more specifically, the treatment of haematological cancer.Peer reviewedServicio Andaluz de Salud, Consejo Superior de Investigaciones Científicas (España)A1 Solicitud de patente con informe sobre el estado de la técnic